Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|21|2075-2084

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.21, 2008-07, pp. : 2075-2084

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 6, 2011-06 ,pp. : 519-527

Bentham Science Publishers

Access to resources Recommend Favorite

The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 823-833

Bentham Science Publishers

Access to resources Recommend Favorite

The Potential of Peroxisome Proliferator-Activated Receptor &ggr; (PPAR&ggr;) Ligands in the Treatment of Hematological Malignancies

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 9, 2007-09 ,pp. : 877-887

Bentham Science Publishers

Access to resources Recommend Favorite

TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies

By  

Current Pharmaceutical Design, Vol. 10, Iss. 29, 2004-11 ,pp. : 3673-3681

Bentham Science Publishers

Access to resources Recommend Favorite

Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies

By  

Current Medicinal Chemistry, Vol. 18, Iss. 12, 2011-04 ,pp. : 1757-1764

Bentham Science Publishers

Access to resources Recommend Favorite